Compare JJSF & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | MESO |
|---|---|---|
| Founded | 1971 | 2004 |
| Country | United States | Australia |
| Employees | 1800 | 81 |
| Industry | Specialty Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.2B |
| IPO Year | 1995 | N/A |
| Metric | JJSF | MESO |
|---|---|---|
| Price | $85.71 | $14.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $140.00 | N/A |
| AVG Volume (30 Days) | ★ 290.1K | 199.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $1,022,038,000.00 | N/A |
| Revenue This Year | $0.87 | $633.98 |
| Revenue Next Year | $1.88 | $29.51 |
| P/E Ratio | $1,736.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $80.00 | $9.61 |
| 52 Week High | $144.37 | $21.50 |
| Indicator | JJSF | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 45.94 | 29.55 |
| Support Level | $80.83 | $10.14 |
| Resistance Level | $87.36 | $16.32 |
| Average True Range (ATR) | 2.95 | 0.50 |
| MACD | 0.46 | -0.24 |
| Stochastic Oscillator | 70.84 | 13.37 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.